{
    "pmcid": "8768012",
    "qa_pairs": {
        "How do camelid-derived nanobodies neutralize SARS-CoV-2?": [
            "By binding to the receptor-binding domain (RBD) of the spike protein, blocking its interaction with the ACE2 receptor.",
            "By binding to the nucleocapsid protein, preventing viral replication.",
            "By binding to the membrane protein, disrupting viral assembly.",
            "By binding to the envelope protein, inhibiting viral release."
        ],
        "In which expression systems can camelid-derived nanobodies be efficiently produced?": [
            "Bacteria (E. coli), yeast (Pichia pastoris), and mammalian cells.",
            "Bacteria (E. coli), fungi (Aspergillus), and plant cells.",
            "Yeast (Saccharomyces cerevisiae), algae, and insect cells.",
            "Fungi (Aspergillus), algae, and mammalian cells."
        ],
        "What advantage do multivalent nanobodies have against SARS-CoV-2 variants?": [
            "They exhibit increased avidity for the ACE2 binding domain and can recognize conserved epitopes.",
            "They exhibit decreased avidity for the ACE2 binding domain and can only recognize unique epitopes.",
            "They exhibit increased avidity for the nucleocapsid protein and can recognize variable epitopes.",
            "They exhibit decreased avidity for the nucleocapsid protein and can only recognize conserved epitopes."
        ],
        "What are the unique properties of camelid-derived nanobodies that make them suitable for targeting viral epitopes?": [
            "They are small, stable, soluble, and can bind to concave epitopes inaccessible to conventional antibodies.",
            "They are large, unstable, insoluble, and can only bind to flat epitopes.",
            "They are small, unstable, insoluble, and can bind to flat epitopes.",
            "They are large, stable, soluble, and can only bind to concave epitopes."
        ],
        "What is a potential method of administration for camelid-derived nanobodies in treating respiratory infections like COVID-19?": [
            "Inhalation, achieving high pulmonary concentrations with minimal systemic exposure.",
            "Oral administration, achieving high gastrointestinal concentrations with minimal pulmonary exposure.",
            "Intravenous injection, achieving high systemic concentrations with minimal pulmonary exposure.",
            "Topical application, achieving high skin concentrations with minimal systemic exposure."
        ]
    }
}